Conferees accept federal definition of "life-threatening" in HB 701-FN but leave eligibility, provider scope and conscience protections unresolved

Conferees on House Bill 701-FN, a bill addressing access to investigational drugs, biologics and devices for patients with terminal illnesses, agreed to adopt federal language for defining "life-threatening" or "terminal" illness but did not resolve three major outstanding issues: the definition of an eligible facility, which licensed providers may offer investigational treatments, and legal protections for physicians who decline to provide requested treatments.

Senators and representatives spent substantial time debating the definition of a terminal or life-threatening condition. Several conferees recommended relying on federal standards. One conferee read the U.S. Food and Drug Administration regulation at 21 C.F.R. § 312.81, which the participants said defines "life-threatening" to include diseases where "the likelihood of death is high unless the course of the disease is interrupted" and conditions "with potentially fatal outcomes where the endpoint of a clinical trial analysis is survival." Another conferee referenced Social Security guidance (DI 23020.045) as an alternative federal definition. After review and caucusing, conferees reported they were "comfortable" using the FDA definition currently cited in the conference materials.

The session moved beyond definitions into practical implementation questions. Representative Leon, who spoke frequently in the discussion, emphasized the intent of the bill is to make investigational options available to patients who face imminent death and to provide a protective legal environment so manufacturers, facilities and clinicians will participate without fear of litigation. Members pressed on who may provide access: the house draft specified "physician providing access" for investigational drugs, biologics or devices, but lawmakers and legal advisers debated whether to explicitly include physician teams, physician assistants, nurse practitioners or other licensed personnel. Conferees noted that while physicians are typically the gatekeepers for experimental treatments, nurses and other staff are essential to delivery and follow-up care; the liability protection language in the senate draft uses broader phrases such as "health care provider, facility, manufacturer, pharmacist, or person or entity involved in the care of the patient," which supporters said is intended to shield all participants in the chain of care.

Conference members also raised the question of where the treatments could be offered and whether an "eligible facility" definition in the senate text should remain or be revised. The senate conferees signaled the eligible-facility language would be one of three items they wanted more time to negotiate. They also sought explicit protections for licensed physicians who, on conscience or other grounds, decline to provide a requested investigational therapy.

The committee recessed to caucus and scheduled a reconvening the following day (02:00) to continue negotiations. When the conference later reconvened, the chair reported the groups "would be comfortable" moving forward with the FDA-provided definition of life-threatening disease but reiterated that eligible facility language, the definition of licensed physician, and protections for physicians who decline treatment remained open for further work.

No final conference report or binding text was issued at the session recorded in the transcript; conferees agreed to continue negotiations and to exchange written proposals before reconvening.